An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. by Heard, Jeffrey J et al.
UCLA
UCLA Previously Published Works
Title
An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF 
resulting in cancer transformation.
Permalink
https://escholarship.org/uc/item/6xt1z4wd
Journal
BMC cancer, 18(1)
ISSN
1471-2407
Authors
Heard, Jeffrey J
Phung, Ivy
Potes, Mark I
et al.
Publication Date
2018-01-10
DOI
10.1186/s12885-017-3938-5
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
An oncogenic mutant of RHEB, RHEB Y35N,
exhibits an altered interaction with BRAF
resulting in cancer transformation
Jeffrey J. Heard1, Ivy Phung1, Mark I. Potes1 and Fuyuhiko Tamanoi1,2*
Abstract
Background: RHEB is a unique member of the RAS superfamily of small GTPases expressed in all tissues and conserved
from yeast to humans. Early studies on RHEB indicated a possible RHEB-RAF interaction, but this has not been fully
explored. Recent work on cancer genome databases has revealed a reoccurring mutation in RHEB at the Tyr35 position,
and a recent study points to the oncogenic potential of this mutant that involves activation of RAF/MEK/ERK signaling.
These developments prompted us to reassess the significance of RHEB effect on RAF, and to compare mutant and wild
type RHEB.
Methods: To study RHEB-RAF interaction, and the effect of the Y35N mutation on this interaction, we used transfection,
immunoprecipitation, and Western blotting techniques. We generated cell lines stably expressing RHEB WT, RHEB Y35N,
and KRAS G12V, and monitored cellular transforming properties through cell proliferation, anchorage independent
growth, cell cycle analysis, and foci formation assays.
Results: We observe a strong interaction between RHEB and BRAF, but not with CRAF. This interaction is dependent on
an intact RHEB effector domain and RHEB-GTP loading status. RHEB overexpression decreases RAF activation of the RAF/
MEK/ERK pathway and RHEB knockdown results in an increase in RAF/MEK/ERK activation. RHEB Y35N mutation has
decreased interaction with BRAF, and RHEB Y35N cells exhibit greater BRAF/CRAF heterodimerization resulting in
increased RAF/MEK/ERK signaling. This leads to cancer transformation of RHEB Y35N stably expressing cell lines,
similar to KRAS G12 V expressing cell lines.
Conclusions: RHEB interaction with BRAF is crucial for inhibiting RAF/MEK/ERK signaling. The RHEB Y35N mutant
sustains RAF/MEK/ERK signaling due to a decreased interaction with BRAF, leading to increased BRAF/CRAF
heterodimerization. RHEB Y35N expressing cells undergo cancer transformation due to decreased interaction
between RHEB and BRAF resulting in overactive RAF/MEK/ERK signaling. Taken together with the previously
established function of RHEB to activate mTORC1 signaling, it appears that RHEB performs a dual function; one is
to suppress the RAF/MEK/ERK signaling and the other is to activate mTORC1 signaling.
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Background
Ras homolog enriched in brain (RHEB) is a member of
the Ras superfamily of small GTPases that are respon-
sible for the activation of numerous important signaling
pathways in the cell [1]. RHEB was discovered as a gene
expressed in neuronal cells after synaptic stimulation
and in the hippocampus after seizures [2]. Later studies
revealed RHEB to be expressed ubiquitously in all tissues
[3–6]. RHEB is a 21 kDa protein that is 37% identical to
KRAS, and shares important features common to small
GTPases including five guanine nucleotide binding
domains, 6/9 identical amino acids of the Ras effector
domain, and a C-terminal CAAX motif that is post-
translationally farnesylated [2, 7]. RHEB, like all small
GTPases, act as molecular switches in the cell; they
switch “on” and activate downstream signaling when
bound GTP, and they switch “off” when bound GDP
through GTP hydrolysis [7]. However, structural studies
have revealed key differences between RHEB and other
members of the Ras superfamily of GTPases [8–10]. A
conserved amino acid important for GTP hydrolysis,
Gln64 (Gln61 in Ras), is buried in a hydrophobic core
blocking access to GTP [8]. These unique structural dif-
ferences cause RHEB to exist in an active GTP-bound
state at higher levels than most small GTPases.
Analysis of cancer genomic databases has revealed a
reoccurring point mutation in RHEB at tyrosine 35. This
mutation has been identified in three patients with clear
cell renal cell carcinoma (ccRCC) and two patients with
endometrial cancers [11]. RHEB Y35N was found to be
significant in ccRCC due to its relatively high mutation
rate relative to background and the location of the muta-
tion in an evolutionarily conserved site [11]. Tryosine 35
is present in the highly-conserved effector domain
region of small GTPases, a region that facilitates inter-
action with downstream proteins and signaling activa-
tion. It is possible due to the location of this mutation,
that it alters RHEB interaction with proteins and there-
fore alters downstream RHEB signaling pathways. Inter-
estingly, RHEB Y35N exerts transforming effects on
NIH3T3 cells as strong as that observed with KRAS
G12 V transforming mutant, and this involves ERK
signaling [12].
Early studies on RHEB looked at the ability of RHEB
to stimulate Ras effectors mainly due to the strong simi-
larities between RHEB and Ras effector domains. It was
demonstrated that purified RHEB could interact with
RAF-1 in vitro or in a yeast two-hybrid assay [4, 13].
Later studies indicated that RHEB binds BRAF and in-
hibits BRAF activation of the RAF/MEK/ERK signaling
pathway [14–16]. However, biological significance of the
RHEB/RAF interaction was not fully explored. Concur-
rent studies revealed RHEB to activate mTORC1 signal-
ing and the field of RHEB research shifted significantly
to the study of mTOR [17, 18]. mTORC1 is a kinase
complex that stimulates protein synthesis and cell prolif-
eration [19]. Aberrant RHEB/mTORC1 signaling has
been linked to many overgrowth diseases including
Lymphangioleiomymoatosis (LAM), Tuberous Sclerosis
(TS), Peutz-Jeghers syndrome (PJS) and benign tumor
formation [20–22].
We, as well as others, have continued to explore iden-
tification of downstream effectors of RHEB, as many
GTPases have been shown to interact with multiple
downstream effectors [23]. In fact, the presence of mul-
tiple downstream effectors is a common feature of the
RAS superfamily GTPases. For example, RAS has been
shown to activate PI3K, RalGDS, RIN1, RAF, and PKC
[24]. Recent publications have linked RHEB to diverse
cellular pathways through interactions with AMPK,
phospholipase D1 (PLD1), β-secretase (BACE1), PDE4D,
and GAPDH [25–29]. Our group recently discovered a
novel RHEB interaction with carbamoyl-phosphate
synthetase II, aspartate transcarbamoylase, and dihy-
drooorotase (CAD), resulting in stimulation of pyrimi-
dine nucleotide biosynthesis in the cell [30]. As
described in this paper, BRAF can be added as another
downstream effector of RHEB.
Above developments concerning RHEB prompted us
to re-evaluate RHEB-RAF interaction. In this paper we
report a strong interaction between RHEB and BRAF
that results in decreased BRAF-CRAF dimerization and
decreased RAF/MEK/ERK signaling. This relationship is
dependent on an intact effector domain and the GTP
loading status of RHEB. Additionally, the Y35N muta-
tion decreases RHEB-BRAF interaction, resulting in
increased BRAF-CRAF dimerization and activation of
RAF/MEK/ERK signaling. Cell lines stably expressing
RHEB Y35N exhibit cancer transformation properties
similar to KRAS G12 V. This evidence suggests that
RHEB regulates the RAF/MEK/ERK pathway from aber-
rant overactivation.
Methods
Cell culture and transfection
HEK293T and NIH 3 T3 cells were obtained from ATCC
(ATCC Numbers CRL-3216 and CRL-1658, respect-
ively). HEK293T and NIH 3T3 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (vol/vol) fetal bovine serum and 1%
(vol/vol) penicillin/streptomycin. Cells were cultured at
37 °C in a 5% CO2 incubator. Transfection was carried
out using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions.
FLAG Immunoprecipitation
HEK293T cells expressing FLAG tagged RHEB -WT,
−T38A, -Y35N, -D60I, and KRAS-G12V were
Heard et al. BMC Cancer  (2018) 18:69 Page 2 of 11
immunoprecipitated using anti-FLAG M2 magnetic
beads (Sigma). Briefly, the cells were lysed with lysis buf-
fer (50 mM HEPES pH 7.4, 150 mM NaCl, 0.4%
CHAPS, 1X Complete EDTA-free protease inhibitor
cocktail (Roche), 1 mM Na3VO4), 150 mM NaCl,
25 mM MgCl2), and the supernatant was cleared of cel-
lular debris using centrifugation (16,000×g for 10 min).
Cleared supernatant was mixed with anti-FLAG M2
magnetic beads (Sigma) for affinity purification. The
beads were collected, washed four times with lysis buf-
fer. The remaining bound proteins were eluted three
times with lysis buffer containing 62 μg/mL of 3X FLAG
peptide. Eluted proteins were concentrated using
Amicon Ultra 0.5-ml centrifugal filters NMWL 10 K
(EMD Millipore, Billerica, MA).
Western blotting & antibodies
The amount of total protein concentration in cellular
lysate was determined by Bio-Rad protein assay accord-
ing to manufacturer’s instructions. Western blotting was
carried out as described previously [31]. Briefly, equal
protein extracts from samples were separated by
SDS-PAGE and transferred onto nitrocellulose mem-
brane (GE Healthcare). The membrane was blocked in
5% bovine serum albumin, incubated in primary anti-
bodies, and followed by incubation in secondary anti-
bodies conjugated to Horseradish peroxidase (HRP). The
membrane was incubated in Pierce ECL Western
Blotting Substrate solution (Thermo Scientific) to acti-
vate the HRP activity, and protein bands were detected
on film.
The following antibodies were purchased from Cell
Signaling Technologies: Anti –RHEB, -KRAS, -ACTIN,
-totalS6, -phosphoS6, -totalERK, -phosphoERK, -BRAF,
and –CRAF. Anti-FLAG was purchased from Sigma.
Generation of Lentivirus and stably expressing cell lines
Stably expressing cell lines were generated using lenti-
viral transduction method. The RHEB and KRAS G12V
genes were amplified from pcDNA.3 plasmid vectors
already containing Flag-RHEB or Flag-KRAS G12V via
PCR, and primers containing EcoRI and BamHI restric-
tion enzyme cut sites. Amplified products were ligated
into the lentiviral transfer plasmid pCCL-c-MCS, after it
was digested with EcoRI and BamHI, using ligase. The
RHEB Y35N mutation was generated using Quickchange
Lighting Site-Directed Mutagenesis Kit (Agilent).
Lentivirus was produced by transfecting the lentiviral
transfer plasmid, the packaging plasmid (pCMV-R8.9)
and the envelope plasmid (pMDG-VSVG) into HEK
293T cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The media
was collected 48 h later and filtered through a 0.45 μm
filter. Lentiviral media was stored at −80 °C until ready
for use.
NIH 3T3 cells were grown until 90% confluency before
adding a mixture of 50% normal media, 50% lentiviral
media, and 8 μg/mL polybrene. Cells were incubated for
48 h before being passaged and grown in normal media.
Expression of transduced proteins were monitored via
Western blot using anti-FLAG antibodies.
Growth curve assay
Cells were grown under normal conditions (DMEM con-
taining 10% FBS) or serum starved (DMEM without
FBS) and measured at given timepoints using the Cell
Counting Kit-8 (Dojindo Molecular Technologies, Inc.)
according to manufacturer’s instructions. Briefly, cells
were grown in 96 well plates, 10 μl of CCK-8 dye was
added to each well containing 100 μl of cell media, cells
were incubated for 1 h, and then readings were obtained
in triplicates using a Spectramax Plus 384 spectropho-
tometer (Molecular Devices) at O.D. 450 nm.
Cell cycle analysis
NIH 3T3 cell lines were trypsinized, washed, and sus-
pended in PBS. Cells were fixed for 1 h at 4 °C in 70%
ethanol. After fixation, cells were washed of ethanol and
suspended in 500 μl of PBS. 20 μl of RNAase A (10 mg/
mL stock) and 25 μl of propidium iodide (1 mg/mL
stock) solutions were added and the cells were incubated
at 37 °C for 30 min. Cells were analyzed by flow cytome-
try at the UCLA Flow Cytometry Core.
Foci formation
NIH 3T3 cell lines were grown under normal growth
conditions for 3 weeks, fresh media was added every
2-3 days. Cells were visualized with crystal violet staining
method. Briefly, cells were fixed with ice-cold methanol
for 10 min on ice. Methanol was removed and the cells
were incubated in 0.5% crystal violet solution (0.5 g crys-
tal violet in 100 ml of 25% methanol solution) for 5 min
at room temperature. Cells were rinsed with H2O until
no more color came off in the rinse. For quantification,
only those foci that were > than 2.5 mm in diameter
were counted.
Soft agar Colony formation assay
To generate a semi-solid media growth surface for cells,
first a 1% and a 0.6% (mass/vol) agar-media solution was
made and autoclaved. Then a 0.5% base-layer-matrix
was generated by heating up the 1% agar solution until
dissolved, and mixing it with normal growth media in a
50:50 ratio. The solution was layered onto a cell culture
plate and left to solidify in the cell incubator for 1 h.
The 0.6% agar solution was heated until dissolved, and
placed in 37 °C H2O bath to bring down to cell
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temperature. The NIH 3T3 cell lines were trypsinized
and suspended in normal media and the 0.6% agar solu-
tion in a 50:50 ratio (now a 0.3% agar-media-cell solu-
tion). The 0.3% agar-media-cell solution was layered on
top of the 0.5% solidified base-layer-matrix. Cells were
grown in incubator as normal for 3–4 weeks, with small
amount of normal media added 1×/week to prevent the
gels from drying out. Cells were incubated with Nitro
Blue Tetrazolium dye 1 mg/ml stock (tablets purchased
from Sigma) overnight at 37 °C. Colonies were visualized
using BioRad Imager and counted by eye.
Results
RHEB interacts with BRAF not CRAF and the RHEB-BRAF
interaction is dependent on the intact effector domain
and GTP binding
It has been reported that RHEB interacts with RAF ki-
nases, however, reports are conflicting on whether RHEB
binds both BRAF and CRAF, or just BRAF [4, 13, 15,
32]. We performed immunoprecipitation of RHEB pro-
tein from cells to identify potential interaction between
RHEB and RAF. Briefly, plasmids expressing Flag-tagged
RHEB were transiently transfected into HEK 293 T cells,
and immunoprecipitation using anti-FLAG antibody was
performed. We observed a strong interaction with RHEB
and BRAF (Fig. 1a). However, we see no interaction be-
tween RHEB and CRAF (Fig. 1a).
The RHEB-BRAF interaction is dependent on an intact
effector domain. This was examined using the RHEB
T38A mutant. The T38A mutation occurs in the RHEB ef-
fector domain, and causes decreased interactions between
RHEB and its effector proteins such as mTORC1 [18, 33].
As seen in Fig. 1b, we observed BRAF interaction was
weaker with the RHEB mutant compared with the wild
type, indicating that the RHEB-BRAF interaction is con-
sistent with RHEB effector protein interactions.
Another RHEB mutant we used is RHEB D60I. The
mutation occurs in a critical region required for GTP
loading, and thus results in a higher amount of inactive
RHEB-GDP and decreased RHEB signaling [18, 34]. As
shown in Fig. 1b, the RHEB D60I interacted with BRAF
less efficiently compared with the wild type, suggesting
that the RHEB-BRAF interaction is dependent on RHEB
GTP-binding status.
RHEB inhibits the RAF/MEK/ERK pathway
To test whether this RHEB-BRAF interaction affects the
RAF/MEK/ERK pathway, we generated a RHEB knock-
down HEK 293T cell line stably expressing RHEB
shRNA. ERK activation can be observed through
Fig. 1 RHEB interacts with BRAF, decreasing BRAF/CRAF heterodimerization and RAF/MEK/ERK signaling. a Immunoprecipitation of FLAG-RHEB from HEK
293T cell lysate, and Western blot of CRAF, BRAF, and FLAG. b FLAG tagged RHEB WT, T38A, and D60I were expressed in HEK 293T cells. Cell lysates were
collected and anti-FLAG immunoprecipitation was performed followed by Western blot for BRAF and FLAG. c Western blot showing levels of RHEB,
phosphorylated ERK, total ERK, phosphorylated S6K, total S6 K and ACTIN in normal and RHEB knockdown HEK 293T cell lines. Compare the amount of
phosphorylated ERK relative to the total amount of ERK. d Western blot showing levels of RHEB, phosphorylated ERK, total ERK and ACTIN in normal and
overexpressed-RHEB HEK 293T cell lines. Compare the amount of phosphorylated ERK relative to the total amount of ERK. e Endogenous BRAF was
immunoprecipitated from HEK 293T cells containing endogenous RHEB or overexpressed RHEB. Western blot of RHEB, CRAF, and BRAF is shown
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increased levels of phosphorylated Thr202 and Tyr204
of ERK protein. We collected the cell lysate from our
RHEB shRNA expressing cell line, and performed a
Western blot using an antibody against phosphorylated
ERK (Thr202/Tyr204). We observed increased levels of
ERK phosphorylation in the RHEB shRNA1 cell lines
(Fig. 1c). As a control, we also saw a decrease in the
levels of phosphorylated S6 K, indicating inhibition of
mTORC1 activity (Fig. 1c).
Additionally, we overexpressed RHEB in HEK 293 T
cells and observed a decrease in the levels of phosphory-
lated ERK (Thr202/Tyr204) in these cells (Fig. 1d).
These results strongly suggest that RHEB inhibits the
RAF/MEK/ERK pathway.
RHEB inhibits BRAF/CRAF Heterodimerization
We tested how the interaction between RHEB and BRAF
could decrease the RAF/MEK/ERK pathway. It is known
that BRAF homodimerization, or heterodimerization
with CRAF, is required for activation of the RAF/MEK/
ERK pathway [35–37]. It was previously suggested that
RHEB-RAF interaction could disrupt BRAF/CRAF
heterodimerization [15]. To test this hypothesis we mon-
itored changes in the levels of BRAF-CRAF dimerization
in cells with different levels of RHEB expression. We
performed immunoprecipitation of BRAF followed by
Western blot for CRAF to observe the amount of BRAF
complexed with CRAF. BRAF-CRAF dimerization was
significantly decreased in the presence of overexpressed
RHEB (Fig. 1e). This suggests that RHEB prevents
BRAF-CRAF dimerization, thus leading to decreased
RAF/MEK/ERK activation.
RHEB Y35N binds BRAF less effectively than RHEB WT
resulting in increased BRAF/CRAF Heterodimerization
An oncogenic mutant of RHEB was identified from the
analysis of human cancer genome databases [11]. It has
recently been reported that RHEB Y35N transforms cells
through and activation of ERK was detected [12]. Since
RAF kinase is upstream of RAF/MEK/ERK, we postu-
lated that the Y35N mutation could affect the RHEB-
BRAF interaction leading to changes in RAF/MEK/ERK
activation. We expressed FLAG-tagged RHEB WT or
RHEB-Y35N in HEK293T cells, collected the cell lysates,
and performed an immunoprecipitation using anti-
FLAG antibody. Western blot analysis using BRAF and
CRAF antibodies revealed that RHEB Y35N binds BRAF
less effectively than RHEB WT (Fig. 2a).
We observed decreased BRAF-CRAF dimerization in
the presence of RHEB WT due to strong RHEB-BRAF
interaction, thus it is possible that the decreased RHEB
Y35N-BRAF interaction allows for greater BRAF-CRAF
dimerization. To test this, we performed immunoprecip-
itation of BRAF in NIH 3 T3 cell lines stably expressing
RHEB Y35N, followed by western blot for CRAF. We
see robust BRAF-CRAF heterodimerization in the RHEB
Fig. 2 The Y35N Mutation Disrupts RHEB-BRAF Interaction Resulting in Increased BRAF/CRAF Heterodimerization and Activation. (a) Top: Western blot for
BRAF, CRAF, and FLAG is shown. HEK 293T cells were transfected with plasmids expressing FLAG-RHEB WT, FLAG-RHEB Y35N, or an empty plasmid
expressing no protein (Neg). Cell Lysate was collected 48 h post transfection, and an immunoprecipitation (IP) using anti-FLAG antibody was carried out.
Bottom: Graph showing the percentage of BRAF bound RHEB Y35N compared to RHEB WT. A BRAF/RHEB ratio was determined for RHEB WT and for RHEB
Y35N using ImageJ to calculate the Western blot band intensities of BRAF and FLAG-RHEB as seen in Western blot above. The BRAF/RHEB ratio for RHEB
WT was set to 100%, and RHEB Y35N was normalized to RHEB WT. The graph depicts the results from three separate experiments. b Cell lysates were
collected from NIH 3T3 cell lines stably expressing RHEB WT or RHEB Y35N. Immunoprecipitation of endogenous BRAF was performed from these lysates.
Western blots against CRAF and BRAF are shown. The cell line used for BRAF IP is indicated above the figure as WT (RHEB WT) or Y35N (RHEB Y35N)
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Y35N cell lines compared with the RHEB WT cell lines
(Fig. 2b). We also observed less RHEB Y35N-BRAF
interaction compared with RHEB WT, similar to our re-
sults from HEK293T cells (Additional file 1: Figure S2).
RHEB Y35N activates ERK signaling
To test whether stable expression of RHEB Y35N acti-
vates ERK signaling, we generated NIH 3T3 cell lines
stably overexpressing RHEB Y35N. As controls, we also
generated cell lines stably overexpressing RHEB WT and
KRAS G12V, a strong activator of RAF/MEK/ERK sig-
naling. All three cell lines exhibit a 3–4-fold increase in
RHEB or KRAS expression compared to control cell
lines (Fig. 3a). We grew the cell lines under normal and
serum starved conditions, collected cell lysates, and per-
formed Western blot for phosphorylated and total ERK
protein. In the absence of serum, RAF/MEK/ERK should
be shut down and we expect to see low levels of phos-
phorylated ERK. However, the RHEB Y35N cell line
showed strong activation of the RAF/MEK/ERK pathway
in the absence of serum, similar to the KRAS G12 V cell
line (Fig. 3b). The RHEB WT cell line also showed
slightly elevated levels of phosphorylated ERK, but at
much lower levels than RHEB Y35N or KRAS G12 V
cells. This is likely due to increased KRAS expression in
the RHEB WT cell lines (Fig. 3a). Additionally, in the
same experiment we saw RHEB Y35N cell lines activated
mTORC1 signaling similar to RHEB WT in the absence
of serum (Fig. 3c).
We hypothesized that the RHEB Y35N mutant acti-
vates BRAF in cells through less effective binding, while
RHEB WT binds BRAF stronger and inhibits BRAF sig-
naling. We tested whether overexpression of RHEB WT
in the RHEB Y35N stably expressing cell line would
decrease RAF/MEK/ERK pathway. We transiently
transfected RHEB WT into the RHEB Y35N expressing
cell lines and monitored changes in levels of
phosphorylated-ERK. The expression of RHEB WT in
RHEB Y35N cell lines resulted in a significant decrease of
phosphorylated-ERK (Fig. 3d). This confirms that RHEB
Y35N activates ERK, while RHEB WT shuts it down.
RHEB Y35N transforms cells
We next looked at the ability of RHEB Y35N to trans-
form normal cells into cancer cells. NIH 3T3 cells were
chosen in part because of their sensitivity to Ras mutant
transformation and ease of transfection [38]. Transform-
ation of normal cells into cancer cells is characterized by
examining the following attributes: reduced serum de-
pendence, loss of density-dependent growth inhibition,
and acquisition of anchorage-independent growth [39].
Under normal growth conditions, all cell lines showed
similar growth curves, however, under serum starved
conditions RHEB Y35N cells grew significantly better
than RHEB WTcells (Fig. 4a). RHEB Y35N cell lines appear
to have a growth curve very similar to the KRAS G12V cell
lines, indicative of transformed cancer cell lines.
In addition, RHEB Y35N and KRAS G12V cell lines
progress through the cell cycle in the absence of serum,
while RHEB WT cell lines do not (Fig. 4b). FACS ana-
lysis was carried out to examine cells in different phases
of cell cycle. While all cell lines displayed similar
percentages of cells in the G1/G2/S phases under nor-
mal conditions, only the RHEB WT and Control cell
lines arrested in the G1 phase under serum starvation
(Fig. 4b, Additional file 2: Figure S3). The KRAS G12V
and RHEB Y35N cell lines did not arrest in the G1 phase
under serum starvation, and appeared to have similar
percentages of cells in the G1/G2/S phases as when
grown under normal conditions (Fig. 4b, Additional file
2: Figure S3).
Cellular transformation was evaluated by two different
assays. First, we performed a foci formation assay to test
the ability of the cell lines to grow in multilayers after
several weeks of growth. We observed extensive foci for-
mation in our RHEB Y35N cell lines similar to KRAS
G12V (Fig. 3c). Second, we performed a colony forma-
tion assay in soft agar to test the ability of the cell lines
for anchorage independent growth. We observed a large
number of colonies in both the RHEB Y35N and KRAS
G12V cell lines (>60), and a low number of colonies in
the control and RHEB WT cell lines (<10) (Fig. 4d).
These experiments show that RHEB Y35N transforms
normal cells into cancer cells similar to KRAS G12V.
RHEB Y35N transforms cells through RAF/MEK/ERK
pathway
Due to the decreased binding with BRAF, the activation
of ERK, and the similar cancer transformation properties
to KRAS G12V, we wanted to test whether RHEB Y35N
transforms cells through the RAF/MEK/ERK pathway.
Using a potent MEK inhibitor (U0126) we see that
RHEB Y35N and KRAS G12V cell viability is signifi-
cantly decreased after 48 h of treatment, whereas RHEB
WT cells are less effected (Fig. 5a). Additionally, the
growth curves of RHEB Y35N and KRAS G12V are
significantly decreased in the presence of 10 μM
U0126, while RHEB WT cell lines are much less af-
fected (Fig. 5b). In similar experiments using the
mTORC1 inhibitor rapamycin, we observed RHEB Y35N
growth was not greatly affected (Fig. 5c and d). This sug-
gests RHEB Y35N transforms cells through the RAF/
MEK/ERK pathway independent of mTOR signaling.
Discussion
In this paper, we have shown that RHEB interacts with
BRAF. Use of two RHEB mutants, T38A and D60I
Heard et al. BMC Cancer  (2018) 18:69 Page 6 of 11
established that this interaction is dependent on the in-
tact effector domain as well as on GTP binding status.
Thus, BRAF is a downstream effector of RHEB. On the
other hand, we have not detected interaction of RHEB
with CRAF, suggesting that RHEB specifically interacts
with BRAF. The reason RHEB binds BRAF and not
CRAF needs further investigation. BRAF and CRAF are
very similar in homology, with only a few differences
Fig. 3 Cell Lines Stably Expressing RHEB Y35N Activate RAF/MEK/ERK Signaling Similar to KRAS G12 V Cell Lines. (a) NIH 3 T3 cell lines stably expressing
RHEB WT, RHEB Y35N, or KRAS G12V were generated using lentiviral transduction. Left: Western blot of FLAG, RHEB, KRAS, and ACTIN protein in total cell
lysates collected from NIH3T3 cell lines stably expressing RHEB WT, RHEB Y35N, KRAS G12V, or an empty vector expressing no protein (Ctrl). Right: Fold
expression for RHEB was calculated by identifying all band intensities using ImageJ analysis, then finding the ratio of RHEB/ACTIN for each sample. The
Ctrl sample RHEB/ACTIN ratio was set at 1. All other samples’ ratios were normalized to Ctrl. KRAS fold expression was calculated same as RHEB. Graph
represents the averages of experiments (n = 2). b NIH 3T3 cell lines stably expressing RHEB WT, RHEB Y35N, KRAS G12 V, or Ctrl were grown in the
presence or absence of serum, and cell lysates were collected after 24 h. Western blot was performed using antibodies for phosphorylated –ERK, and
total –ERK. Fold expression for pERK was calculated as in (a). Briefly, band intensities as determined by ImageJ were used to find the ratio of pERK/total
ERK for each cell line and condition. The ratio for Ctrl under normal growth conditions was set to 1, and all other ratios were normalized
to Ctrl under normal growth conditions. Graph represents the averages of experiments (n = 2). c Same experiment as performed in
(b), except looking at phosphorylated –S6, and total –S6. Fold expression for pS6 was calculated as in (b). d NIH 3 T3 cell lines stably
expressing Y35N were transiently transfected with plasmids to overexpress RHEB WT. Left: Western blot for phosphorylated-ERK (pERK) is
shown. Right: Graph showing ERK activation based on levels of phosphorylated ERK compared to total ERK. The pERK/totalERK ratio for RHEB Y35N
and RHEB Y35N + RHEB WT cell lines, was determined by quantifying the intensities of the Western blot bands for pERK and totalERK using imageJ.
The graph shows results from three separate experiments
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between them. Most notably, BRAF has an extended
portion of the N-terminus that is not present in CRAF.
It has been reported that this extra N-terminal sequence
facilitates RAS binding with BRAF differently than with
CRAF [40]. It could be that this is the area where RHEB
interacts, but further studies are needed to determine
the RHEB binding site on BRAF. We further showed
that RHEB inhibits BRAF-CRAF dimer formation.
Significance of RHEB-BRAF interaction was further
supported by the experiment to knockdown RHEB.
Increased ERK signaling was observed when RHEB ex-
pression was inhibited by shRNA. In contrast, overex-
pression of RHEB results in the inhibition of the ERK
signaling. Thus, RHEB suppresses the ERK signaling
through its interaction with BRAF and inhibition of the
formation of BRAF-CRAF heterodimer.
Fig. 4 RHEB Y35N Transforms Cells Similar to KRAS G12V and RHEB WT Does Not. (a) Growth curves of NIH 3T3 cell lines stably expressing RHEB WT,
RHEB Y35N, or KRAS G12 V grown in media containing 10% FBS (left), or serum-free media (right), for 7 days. Fold Growth was calculated as follows:
(OD at day X) / (OD at day 0), where OD was read according to Cell Counting Kit-8 (Dojindo Mol. Tech.) protocol. Error bars are the standard deviation
measured from three separate experiments. b NIH 3T3 stably expressing cell lines were grown for 2 days with serum (left) or without serum (right).
Cells were then fixed, treated with RNase A to remove RNA, and incubated with propidium iodide (PI) to dye DNA. Cells were grouped into cell cycle
stage based on PI intensity measured using flow cytometry. Graphs show the percentages of cells at each stage in the cell cycle. c Foci Formation
Assay. NIH 3T3 stably expressing cell lines were grown under low serum conditions for 3 weeks. Cells were fixed with methanol and stained with
crystal violet dye for easy visualization. d Soft Agar Colony Formation Assay. NIH 3T3 stably expressing cell lines were grown in agar-media suspension
for 3 weeks. Plates were incubated overnight with Nitroblue Tetrazolium Chloride (NBT) in order to visualize colonies on a gel imager
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The oncogenic RHEB mutant Y35N was identified in
human cancers including renal cancer and endometrial
cancer [11]. We have shown the oncogenic RHEB mu-
tant, RHEB Y35N, interacts less efficiently with BRAF
when compared with the wild type RHEB. Furthermore,
the Y35N mutant does not inhibit BRAF-CRAF hetero-
dimerization, while the wild type RHEB does. Thus, ERK
signaling is sustained at a higher level in mutant cells
than in wildtype, contributing to transformation. On the
other hand, the RHEB Y35N mutant behaves similarly to
the wild type with respect to the activation of mTORC1
signaling. We also examined the binding of the mutant
RHEB Y35N to AMPK, as a previous report suggested
that RHEB Y35N transforms cancer cells through an
interaction with AMPK [12]. This paper argues that
RHEB Y35N displays stronger binding to AMPK, which
prevents AMPK from phosphorylating and inhibiting
BRAF. However, in our experiments we did not observe
increased binding of RHEB Y35N to AMPK when com-
pared with the RHEB WT (Additional file 3: Figure S1).
Transforming capability of the RHEB Y35N mutant
was evaluated by establishing a stable cell line expressing
the mutant RHEB. We find that these cells exhibit
serum independent growth; they avoid G1 cell cycle ar-
rest and continue to grow in the absence of serum.
These cells also exhibit foci formation and soft agar
growth demonstrating anchorage independent growth.
Strikingly, the transforming ability of the RHEB mutant
was as strong as that of the KRAS G12V mutant. In fur-
ther support of the significance of the increased ERK
signaling and not mTORC1 signaling in the Y35N ex-
pressing cells, proliferation of these cells were inhibited
by MEK inhibitor but not by rapamycin.
Presence of multiple downstream effectors is a com-
mon feature of the Ras superfamily GTPases, as
evidenced by identification of multiple downstream ef-
fectors of RAS that includes RAF, PI3K, RalGDS, RIN1
and PKC. Our current study firmly establishes that
BRAF is a critical downstream effector of RHEB. Since it
has been established that mTORC1 is a downstream ef-
fector of RHEB, RHEB affects multiple downstream
signaling pathways. Further work on RHEB signaling
could define the significance of these downstream
signaling pathways and in turn define the function of
RHEB GTPase.
Conclusions
In this paper we report a strong interaction between
RHEB and BRAF that results in decreased BRAF-CRAF
dimerization and decreased BRAF/MEK/ERK signaling.
This relationship is greatly affected by the Y35N point
Fig. 5 RHEB Y35N is Dependent on RAF/MEK/ERK Signaling, not mTORC1 Signaling, for Proliferation in Low Serum Conditions. (a) NIH 3T3 cell lines stably
expressing RHEB WT, RHEB Y35N, or KRAS G12V as well as control were treated with 3 different concentrations of RAF/MEK/ERK inhibitor, U0126, for 48 h.
% Viable Cells = (OD value of treated cells) / (OD value of non-treated cells) * 100. OD values were measured using Cell Counting Kit-8. Error bars represent
standard deviation from three separate experiments, *p < 0.05, **p < 0.01, *** p < 0.001. The four cell lines grow similarly under normal condition as shown
in Fig. 4a. b NIH 3T3 cell lines were grown in serum-free conditions, with or without 10 μM U0126 treatment. Growth was monitored using Cell Counting
Kit-8 for 6 days. Error bars are shown from three repeated experiments (c) RHEB Y35N growth is not sensitive to mTORC1 inhibition. NIH 3T3 cell lines were
treated with 3 different concentrations of mTORC1 inhibitor, Rapamycin, for 48 h. % Viable Cells and statistics calculated as in (a). d NIH 3T3 cell lines were
grown in serum-free conditions, with or without 20 nM Rapamycin treatment. Growth was monitored as in (b)
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mutation, which results in cellular cancer transformation
due to decreased RHEB Y35N-BRAF interaction and
increased BRAF-CRAF dimerization. This evidence
shows a crucial role RHEB has in directly regulating the
RAF/MEK/ERK pathway from aberrant activation,
provides results that deepen our understanding of
RHEB signaling.
Additional files
Additional file 1: Figure S2. RHEB Y35N Exhibits Decreased Binding to
BRAF. Cell lysates were collected from NIH 3T3 cell lines stably expressing
FLAG-RHEB WT or FLAG-RHEB Y35N. Immunoprecipitation of endogenous
BRAF was performed from these lysates. Western blots against BRAF and
FLAG are shown. The cell line used for BRAF IP is indicated above the
figure as WT (RHEB WT) or Y35N (RHEB Y35N) (PDF 161 kb)
Additional file 2: Figure S3. Flow Cytometry Data for Cell Cycle Analysis.
NIH 3T3 cell lines stably expressing FLAG-RHEB WT or FLAG-RHEB Y35N
were grown for 2 days with serum (normal growth, top row) or without
serum (serum starved, bottom row). Cells were then fixed, treated with
RNase A to remove RNA, and incubated with propidium iodide (PI) to dye
DNA. Cells were grouped into cell cycle stage based on PI intensity
measured using flow cytometry. Flow cytometry statistics for each sample is
shown to the right of each graph (PDF 434 kb)
Additional file 3: Figure S1. RHEB Y35N Does not Exhibit Increased
Binding to AMPK. A) RHEB WT, T38A, and Y35N mutants were transiently
transfected and expressed in HEK 293T cells, cell lysates were collected,
and immunoprecipitation for each was carried out. These results show a
Western blot for AMPKα and FLAG from those samples. An effector
domain mutant, RHEB T38A, did not bind AMPK demonstrating that
AMPK is a relevant effector of RHEB (PDF 154 kb)
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